title: Genotype-phenotype relationship in patients with mutations in thyroid hormone transporter MCT8.
abstract: Loss-of-function mutations in thyroid hormone transporter monocarboxylate transporter 8 (MCT8) lead to severe X-linked psychomotor retardation and elevated serum T(3) levels. Most patients, for example those with mutations V235M, S448X, insI189, or delF230, cannot stand, walk, or speak. Patients with mutations L434W, L568P, and S194F, however, walk independently and/or develop some dysarthric speech. To study the relationship between mutation and phenotype, we transfected JEG3 and COS1 cells with wild-type or mutant MCT8. Expression and function of the transporter were studied by analyzing T(3) and T(4) uptake, T(3) metabolism (by cotransfected type 3 deiodinase), Western blotting, affinity labeling with N-bromoacetyl-T(3), immunocytochemistry, and quantitative RT-PCR. Wild-type MCT8 increased T(3) uptake and metabolism about 5-fold compared with empty vector controls. Mutants V235M, S448X, insI189, and delF230 did not significantly increase transport. However, S194F, L568P, and L434W showed about 20, 23, and 37% of wild-type activity. RT-PCR did not show significant differences in mRNA expression between wild-type and mutant MCT8. Immunocytochemistry detected the nonfunctional mutants V235M, insI189, and delF230 mostly in the cytoplasm, whereas mutants with residual function were expressed at the plasma membrane. Mutants S194F and L434W showed high protein expression but low affinity for N-bromoacetyl-T(3); L568P was detected in low amounts but showed relatively high affinity. Mutations in MCT8 cause loss of function through reduced protein expression, impaired trafficking to the plasma membrane, or reduced substrate affinity. Mutants L434W, L568P, and S194F showed significant residual transport capacity, which may underlie the more advanced psychomotor development observed in patients with these mutations.
authors.affiliation: Department of Internal Medicine, Erasmus Medical Center, Room Ee502, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands.
authors.forename: Jurgen
authors.initials: J
authors.lastname: Jansen
authors.forename: Edith C H
authors.initials: EC
authors.lastname: Friesema
authors.forename: Monique H A
authors.initials: MH
authors.lastname: Kester
authors.forename: Charles E
authors.initials: CE
authors.lastname: Schwartz
authors.forename: Theo J
authors.initials: TJ
authors.lastname: Visser
mesh_terms: D000818:Animals; D019556:COS Cells; D002478:Cells, Cultured; D002522:Chlorocebus aethiops; D003459:Crystallins / Q000235:genetics; D005838:Genotype; D006801:Humans; D027501:Monocarboxylic Acid Transporters / Q000235:genetics* / Q000378:metabolism; D016297:Mutagenesis, Site-Directed; D009154:Mutation; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D011597:Psychomotor Performance; D027981:Symporters; D013963:Thyroid Hormones / Q000378:metabolism / Q000493:pharmacokinetics; D014162:Transfection; D000090803:mu-Crystallins
chemical_list: D003459:Crystallins; D027501:Monocarboxylic Acid Transporters; C090735:SLC16A2 protein, human; D027981:Symporters; D013963:Thyroid Hormones; D000090803:mu-Crystallins